新西兰慢阻肺患者长效支气管扩张剂使用模式:全国性新用药者随访研究
研究描述首次治疗方案持续时间、方案使用序列及随访期间使用与停用模式,发现用药模式复杂且常不符合治疗指南。
要点
- 最常启动的方案为LABA联合吸入糖皮质激素(ICS)。
- ICS使用与国际指南不一致,少加重者过度治疗、频加重者治疗不足,ICS单药治疗常见。
- 首次方案中位持续时间为46天,多数患者随时间使用多种方案且停用期常见。
核心结论
- 在新西兰全国性研究中,LABA、LAMA和ICS的使用模式复杂,且常不符合治疗指南。
- 需要进一步工作来解决指南与处方实践之间的差异。
研究设计与样本
- 全国性随访研究,使用国家卫生与药品发放数据识别新用药者。
- 队列共83 435例患者,随访290 400人年。
- 将LABA、LAMA和ICS的发放汇总为治疗方案使用片段。
- 采用Kaplan-Meier曲线、旭日图和序列索引图分别总结首次方案持续时间、独特方案使用序列及随访期间使用与未使用模式。
主要发现
- 最常启动的方案为LABA联合ICS。
- ICS使用与国际指南不一致:少加重患者过度治疗、频加重患者治疗不足,且ICS单药治疗常见。
- 首次方案的中位持续时间为46天。
- 许多患者随时间使用多种方案,未使用期常见。
临床怎么用
- 提示处方实践与慢阻肺治疗指南存在差距,应关注ICS的适用人群及方案转换与停用问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: While several studies have found that prescribing practices do not conform to chronic obstructive pulmonary disease (COPD) treatment guidelines, none have examined longitudinal patterns of use of long-acting beta2 -agonist (LABA) and long-acting muscarinic antagonist (LAMA) therapy across an entire country. We undertook a nationwide follow-up study to describe treatment patterns in new users of long-acting bronchodilators. METHODS: National health and pharmaceutical dispensing data were used to identify patients aged ≥45 years who initiated LABA and/or LAMA therapy for COPD between 1 February 2006 and 31 December 2013. Dispensings of LABAs, LAMAs and inhaled corticosteroids (ICSs) were aggregated into episodes of use of therapeutic regimens. Kaplan-Meier curves, sunburst plots and sequence index plots were generated to summarize, respectively, the duration of the first regimen, the sequences in which unique regimens were used and the patterns of use and non-use during follow-up. RESULTS: The study cohort included 83 435 patients with 290 400 person-years of follow-up. The most commonly initiated regimen was a LABA with an ICS. ICS use was inconsistent with international guidelines: over- and under-treatment occurred in patients with infrequent and frequent exacerbations, respectively, and ICS monotherapy was common. The median duration of the first regimen was 46 days. Many patients used multiple regimens over time and periods of non-use were common. CONCLUSION: In this nationwide study, patterns of use of LABAs, LAMAs and ICSs were complex and often did not comply with treatment guidelines. Further work is required to address the discrepancy between guidelines and prescribing practices.
引用
- Parkin L, Barson D, Zeng J, et al. Patterns of use of long-acting bronchodilators in patients with COPD: A nationwide follow-up study of new users in New Zealand. Respirology. 2017. PMID: 29265705. doi:10.1111/resp.13235
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。